

Full Length Research Paper

A double blind, placebo-controlled, crossover study on the effect of MS₁₄, an herbal-marine drug, on quality of life in patients with multiple sclerosis

Mohsen Naseri¹, Amrollah Ahmadi², Kourosh Gharegozli³, Masoud Nabavi⁴, Soghrat Faghihzadeh⁵, Nevoid Ashtarian⁶, Fariba Montazami⁶ and Hossein Rezaeizadeh⁷

¹Shahed Medicinal Plants Research Center, Head of Department of Traditional Iranian Medicine, Shahed University, P. O. Box: 13185-1678, Tehran, Iran.

²Traditional Iranian Medicine Research Center, Shahed University, P. O. Box: 13185-1678, Tehran, Iran.

³Department of Neurology, Shahid Beheshti University of Medical Science, P. O. Box 13185 - 1678, Tehran, Iran.

⁴Department of Neurology, Faculty of Medicine, Shahed University, P. O. Box: 13185-1678, Tehran, Iran.

⁵Department of Biostatistics, Faculty of Medicine, Tarbiat Modarres University, P. O. Box: 13185-1678, Tehran, Iran.

⁶Loghman Hospital, Shahid Beheshti University of Medical Science, P. O. Box 13185 -1678, Tehran, Iran.

⁷Student's Scientific Research Center, Medical Sciences/University of Tehran, P. O. Box: 13185-1678, Tehran, Iran.

Accepted 31 March, 2009

Current research into new drugs is focused on agents that will change multiple sclerosis process. MS₁₄ is an herbal-marine product, based on anecdotal evidences in traditional Iranian medicine (TIM). The objective of this study was to assess the safety and efficacy of MS₁₄ in volunteer patients. This study was a randomized placebo-controlled, double blind, crossover clinical trial in patients who had not responded to common MS drug regimens. Common toxicity criteria and quality of life (QOL) questionnaire were assessed. No significant changes were observed in vital signs, biochemical, hematological, liver and kidney function tests. Moreover, the improvement of patients' mobility (lower limb) was significant, comparison before treatment and placebo group (p-value: 0.048). These results suggest the potential benefits of MS₁₄ on QOL in patients and attenuating and remodeling of multiple sclerosis disease and although the results confirm the safety and relative efficacy of MS₁₄.

Key words: Multiple sclerosis, MS₁₄, Iranian traditional medicine.

INTRODUCTION

Multiple sclerosis (MS) is characterized by a relapsing remitting or progressive course and a pathologic triad of CNS inflammation, demyelination and gliosis (Braunwald and Fauci, 2005). MS affects thousands of sufferers worldwide and in many cases it is characterized by the relentless progression of the disease with increasing disability. According to recent investigations, treatment with interferon or other disease modifying drugs (DMDs) has limited benefit and some side effects. Furthermore the progression of disease is not much affected by these drugs (Braunwald and Fauci, 2005; Galetta and

Markowitz, 2005; Coyl and Hammad, 2003). So there is a need for newer therapeutics or neuroprotective agents in treatment of MS.

MS₁₄ is an Iranian herbal-marine compound that has been patented by invention and patent registration office of Islamic republic of Iran (no: 29350) and classified as equivalent to food with no observable adverse effect level (NOAEL) (Hajhashemi et al., 2004; Klaassen, 2001). According to analytic data this compound contains many inorganic salts or complexes and also trace elements such as bromine (Br), strontium (Sr), vanadium (V), titanium (Ti), nickel (Ni) and zinc (Zn) (Ahmadi, 2004). One study strongly suggests that MS₁₄ has a protective action against preoperative damage to biomembranes and introduces it as an antioxidant agent (Naderi et al., 2004, unpublished). Sub-acute toxicity study in rats confirms the

*Corresponding author. E-mail: swt_f@yahoo.com.
Tel.: +982166439463. Fax: +9821 66919206.

safety of MS₁₄ (clinical, histopathological, hematological and in blood biochemistry) (Hajhashemi et al., 2004). Anecdotal bits of evidence rooted in Iranian traditional medicine suggest that MS₁₄ could help MS patients and in practice of this system of complementary and alternative medicine, it has been shown to be beneficial in certain multiple sclerosis patients. In the study of MS₁₄ in EAE model (experimental allergic encephalomyelitis) have shown that oral treatment of the EAE mice with MS₁₄ not only halts the progression of the disease but also attenuates the inflammation in CNS indicating that this herbal-marine compound has anti-inflammatory effects (Tafreshi et al., 2008). A small pilot clinical trial on volunteer MS patients also indicated that MS₁₄ may have some benefits on quality of life (QOL) and some symptoms of the patients (Gharegozli, 2004; unpublished data, Department of Neurology, Shahid Beheshti University of medical science). After some reports from minor pilot studies on volunteer patients suffering from MS which indicated the usefulness of MS₁₄, it is incumbent upon us to investigate this drug, for it offers the potential of an oral therapy for MS with few side effects.

Overall, alleviation of clinical and neurological symptoms in EAE mice by MS₁₄ explained the beneficial effects of traditionally used MS₁₄ in MS patients. With the above information at hand, upon receiving the required permit from the respective medical ethics committee, we performed a randomized placebo-controlled crossover study with MS₁₄ on multiple sclerosis patients with cerebellar ataxia who had not responded to common MS drug regimens, to assess the safety and efficacy of MS₁₄.

MATERIALS AND METHODS

Patients

We included MS patients aged at least 18 years, with relapsing-remitting or secondary progressive form of multiple sclerosis according to the McDonald criteria (Diagnostic McDonald Criteria for Multiple Sclerosis, 2008). Patients selected were not to be in an acute attack by at least one month prior to start of the study. They were to demonstrate cerebellar symptoms such as dysmetria or ataxic tremor or gait and no concurrent natural or herbal treatment should have been taken by them.

Exclusion criteria consisted of presence of cardiovascular diseases, pregnancy or breast feeding, relapse during the previous 1 month or during the study, active infectious disease, introduction of new treatments for MS during the previous month, concurrent pharmaceutical drugs for cerebellar ataxia, severe cognitive or psychotic disorder and major disturbance in blood factors (biochemistry and hematology) in primary lab data.

Written informed consent was obtained from the patients before enrollment. The study protocol was approved by research ethics committee of Shahid Beheshti University of medical sciences. The study was conducted according declaration of Helsinki.

Intervention

We used the Poison method for assigning patient to randomly receive either active treatment (D) or placebo (P) as they enter the study, in the 2 phases. In the first phase, patients in group A started

with MS₁₄ (50 mg/kg/day as 500 mg oral caplets divided to 3 doses), being on active medication for 3 weeks before starting placebo and patients in group B started with placebo caplets for 3 weeks. In the second phase, which took place after a 1 month washout period to avoid the fluctuation of clinical examination, the groups were crossed over: group A received placebo group B received MS₁₄ for 3 weeks. All patients, staff involved in administration of the interventions and those assessing the outcomes were blinded by irrelevant supervisor.

Clinical and paraclinical assessments

Each patient was evaluated at the first visit and the end of each phase for common toxicity criteria (CTC V.2) (National Cancer Institute, 2003) and clinical signs and symptoms of MS. CTC included vital signs, liver function, kidney function and urinary, blood and biochemistry tests (Table 1 and 2). Treatment response rate was evaluated in accordance with Hamburg quality of life questionnaire on multiple sclerosis (HAQUAMS) (Gold et al., 2001) and classified to 7 groups including sensory, cognitive and fatigue, upper extremity mobility, lower extremity mobility, urination, defecation, sexuality, communication and mood.

Statistical analysis

All statistical analyses were performed by means of SPSS software (version: 15.0). The assumption of normality was assessed using the Kolmogorov-Smirnov test. P-values less than 0.05 were considered as statistically significant. This crossover study was performed and analyzed based on the methods described in the Pocock clinical trial (Pocock, 1991). Groups were assigned the letter "i" (1 = DP and 2 = PD) where "D" represents drug and "P" represents placebo; the time phases were assigned the letter "j" (1 or 2). For each variable tested, D_{ij} was calculated and corresponded to the post-treatment value minus pre-treatment value for group i during phase j. X_{ij} denotes the post-treatment value for group i in the phase j. This way, the carry-over effect was tested by comparing $D_{11} + D_{12}$ with $D_{21} + D_{22}$ and treatment effect was assessed by comparing $X_{11} - X_{12}$ with $X_{21} - X_{22}$ when there was no evidence of carry-over effect. Statistical evaluation was performed using Mann-Whitney test and the paired Wilcoxon rank sum test.

RESULTS

Patients' characteristics

38 patients (31 women and 7 men) were included in this study; 20 were randomly assigned to group A and the rest comprised group B. The mean age of participants was 30.8 years (range 18 to 56). At the time of the study, patients were receiving 1 or more of the following treatments: interferon-beta (1a or 1b), cyclophosphamide, or methotrexate.

Treatment response

No adverse effects were seen in administration of MS₁₄ with respect to common toxicity criteria in any of the patients studied (Table 1 and 2). A subjective effect on fatigue and cognitive signs was frequently observed with either placebo or MS₁₄. Treatment with placebo and treatment with MS₁₄ both improved the evaluation parameters,

Table 1. Analyzed results of common toxicity criteria evaluation.

Parameters	Differences (treatment effect) ^a			Sums (interaction) ^b		
	Group A (MS14 /Placebo)	Group B (Placebo/ MS14)	P-value	Group A (MS14 /Placebo)	Group B (Placebo/ MS14)	P-value
Red Blood Cell (RBC)	0.8 (0.31)	-0.03 (0.10)	0.399	9.26 (0.60)	9.13 (0/60)	0.815
Hemoglobin	0.68 (2.66)	-0.014 (0.43)	0.735	24.95 (3.88)	26.50 (1/98)	0.000
Hematocrit	0.80 (2.94)	0.29 (2.39)	0.966	80.53 (8.81)	82.37 (7/39)	0.271
White Blood Cell (WBC)	-2.23 (5.72)	-3.23 (7.06)	0.767	13.43 (5.89)	16.20 (8/64)	0.422
Platelet	18.25 (65.26)	-3.83 (35.31)	0.512	513/92 (129.52)	435.17 (57/34)	0.472
Erythrocyte Sedimentation Rate (ESR)	1.00 (7.18)	-0.67 (7.10)	0.962	25.16 (17.74)	22.33 (23.83)	0.190
C-Reactive phase Protein (CRP)	0.23 (0.83)	0.01 (0.02)	0.497	0.24 (0.82)	0.01 (0.01)	0.373
Sodium (Na)	-0.92 (5.30)	0.92 (5.30)	0.876	280.92 (5.50)	278.00 (5.31)	0.152
Potassium (K)	0.20 (0.58)	-0.35 (0.39)	0.036 ^c	8.62 (0.56)	8.25 (0.52)	0.131
Calcium (Ca)	0.37 (0.40)	0.06 (0.82)	0.445	19.07 (0.88)	18.94 (0.73)	0.611
SGOT	1.83 (15.40)	4.50 (6.56)	0.534	44.33 (15.13)	40.25 (10.22)	0.536
SGPT	3.50 (16.52)	-0.75 (10.29)	0.374	48.50 (22.22)	38.75 (15.90)	0.396
Blood Urea Nitrogen (BUN)	-1.72 (8.03)	0.29 (4.3)	0.555	43.8 (12.53)	42.86 (11.51)	0.964
Creatinine (Cr)	-0.19 (0.22)	-0.15 (0.10)	0.918	1.57 (0.25)	1.51 (0.42)	0.479
Urine Analysis	0.33 (1.36)	0.43 (0.53)	0.213	1.00 (1.26)	1.00 (0.82)	0.822

(a) Differences X1–X2: post treatment value for period 1 minus post treatment value for phase.

(b) Sums D1 + D2 where Di designs the post treatment value minus pre treatment value for the phase i (i = placebo or MS₁₄).

(c) Significant interaction effect.

yet, a subjective effect on lower limb motion was observed only with MS₁₄ as indicated in Table 3.

DISCUSSIONS

Significant advances in the treatment of MS have been seen in recent years, but further improvements in therapy are required as all patients do not respond optimally. An approach to enhancing MS treatment is to combine drugs that impact on different aspects of the disease process. Currently, it is increasingly being recognized that combination therapy with existing or novel MS therapeutics may produce a more favorable clinical outcome than monotherapy in the disease and therefore represent the future of MS treatment (Pattia et al., 2004; Giuliana et al., 2005).

The use of complementary and alternative medicine (CAM) and dietary supplements appears to be high amongst the general population for different ailments, and in patients with MS (Hunly and Ernest, 2000; Pucci et al., 2004; Stuijbergen and Harrison, 2003; Simile and Hardy, 2002; Nayak et al., 2003). Because these approaches are not definitely effective, they may be of limited interest to physicians and other conventional health provi-

ders. In contrast, for patients with MS these interventions may be of considerable interest because they may be mildly effective yet significantly inexpensive and relatively safe. Vitamin D, ginkgo biloba, cannabinoids, and Padma 28 produce immunomodulatory actions and therapeutic effects in experimental autoimmune encephalomyelitis (Hunly and Ernest, 2000; Pucci et al., 2004; Stuijbergen and Harrison, 2003; Simile and Hardy, 2002; Nayak et al., 2003). For these compounds, however, there is not enough clinical trial data or safety information to support their use as disease modifying therapies (Hunly and Ernest, 2000; Pucci et al., 2004; Stuijbergen and Harrison, 2003; Simile and Hardy, 2002; Nayak et al., 2003).

In our exploration of complementary and alternative medicine, we are of the following belief that great assets as therapeutic facts lay within different schools of traditional medicine; schools of therapeutics which stood the test of time as seen in 5 thousand years old tradition of Chinese traditional medicine or 8 thousand years old tradition of Iranian traditional medicine. We further believe that the knowledge which lies in the schools of traditional medicine (ethno-medicine), if efficiently used, may lead to novel drug discovery and development through shortened explorative paths based on a reverse pharmacology path (Patwardhan

Table 2. Results of vital signs evaluation in patients, no statistically significant difference was observed.

Placebo		Treatment		Control		Vital signs
S.D	Mean	S.D	Mean	S.D	Mean	
7.67	110.15	8.55	109	11.36	112.89	Systolic Blood Pressure
8.1	78.9	8.14	76.83	8.43	77.73	Diastolic Blood Pressure
5.85	81.87	8.55	82.1	20.19	84.89	Pulse Rate
1.41	12.28	1.66	12.2	10.59	14	Respiratory Rate
0.02	39.92	0.02	36.9	0.15	36.87	Temperature

Table 3. Treatment response rate according to Hamburg quality of life questionnaire in multiple sclerosis (HAQUAMS), analyzed by Wilcoxon test.

Groups	MS ₁₄ (Pretreatment)	Placebo (Pretreatment)	MS ₁₄ / Placebo
Problem			
Sensory	0.436	0.678	0.569
Fatigue and Cognitive	0.036*	0.034*	0.917
Upper Limb motion	0.230	0.752	0.146
Lower Limb motion	0.063*	0.191	0.048*
Urination, Defecations and Sexuality	0.215	1	0.831
Communication	0.357	0.701	0.450
Mood	0.332	0.032	0.584

(*) P-value < 0.05

et al., 2004; Fabricant, 2001). The instance of the use of cannabinoids in the treatment of MS is one such example. Cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale, but they were able to a degree to unmask objective improvement in mobility and augmented the patients' feelings of an improvement in pain (Zajicek et al., 2003). This suggested that cannabinoids may be clinically useful in the treatment of MS (Zajicek et al., 2003) and a standardized *Cannabis sativa* plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs (Vaney et al., 2004).

MS₁₄ is an herbal-marine compound which has been recognized as a remedy in the treatment of MS based on available data within the libraries on CAM. MS₁₄ ameliorates experimental allergic encephalomyelitis (Tafreshi et al., 2008) but our data is subjective and we do not know the mechanisms by which MS₁₄ acts on multiple sclerosis disease. The results of this study confirm the relative safety of this remedy in human but objective studies are required to confirm the efficacy of this natural agent. The present study further demonstrates that MS₁₄ can improve the lower limb mobility which may be due to multiple mechanisms that need to be further investigated.

ACKNOWLEDGMENTS

Shahed medicinal plants research center (related to

Shahed University, Tehran, Iran) undertook disbursements for this study. This center helped to (i) conduct of the study (ii) the collection, analysis and interpretation of data (iii) the writing of the report (iv) the decision to submit the paper for publication. We also appreciate Dr Behnam Sheibani for his review and edition of the english translation of the article.

The authors also would like to thank Farzan institute for research and technology for technical assistance.

REFERENCES

- Ahmadi A (2004). In accordance with report of Atomic Energy Organization of Iran (AEOI), Research Division, Tehran, I.R. of Iran, Analysis of MS₁₄.
- Braunwald E, Fauci AS (2005). Harrison's principles of internal medicine (16th edn). Mc Grow-Hill publication, New York.
- Coyl PK, Hammad MA (2003). Atlas of multiple sclerosis. London: Science press.
- Diagnostic McDonald Criteria for Multiple Sclerosis. Available at: <http://www.mult-sclerosis.org/DiagnosticCriteria.html>
- Fabricant S (2001). The value of plants used in traditional medicine for drug discovery. Environ. Health. Prospect. 109: 69
- Galetta S, Markowitz C (2005). US FDA-Approved Disease-Modifying Treatments for Multiple Sclerosis: Review of Adverse Effect Profiles. CNS. Drugs. 19: 239-252.
- Giuliana F, Metza L, Wilsona T, Fana Y, Bar-Orb A, Yonga V (2005). Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. Neuroimmunol. 158: 213-221.
- Gold SM, Heesen C, Schulz H, Guder U, Mönch A, Gbadamosi J (2001). Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult. Scler. 7:119-130.

- Hajhashemi V, Ghafghazi T, Ahmadi A (2004). Study the sub acute toxicity of natural product MS₁₄ in rat. *Daneshvar (Scientific Research Journal of Shahed University, Iran)* 52:11-14 (in Persian).
- Hunly A, Ernest E (2000). Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review. *Complement. Ther. Med.* 8: 97-105
- Klaassen C (2001). *Casarett and Doull's Toxicology: The basic science of poisons*. McGraw-Hill, New York.
- National Cancer Institute. Common terminology criteria for adverse events, V 3.0. Available at: <http://ctep.cancer.gov/forms/CTCAEV3pdf>. Accessed June 2003.
- Nayak S, Matheis RJ, Schoenberger NE, Shiflett SC (2003). Use of unconventional therapies by individuals with multiple sclerosis. *Clin. Rehabil.* 17:181-191.
- Pattia F, Amatob MP, Filippic M, Gallod P, Trojanoe M, Comi GC (2004). A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. *Neurol. Sci.* 223:69-71.
- Patwardhan B, Vaidya ADB, Chorghade M (2004). Ayurveda and natural product drug discovery. *Cur. Sci.* 86:789.
- Pucci E, Cartechini E, Taus C, Guiliani G (2004). Why physicians need to look more closely at the use of Complementary and alternative medicine by multiple sclerosis patients. *Eur. J. Neurol.* 11:263-267.
- Pocock SJ (1991). *Clinical trials: A practical approach*. John Wiley and sons publication, New York, pp110-122.
- Simile Ni H, Hardy C (2002). Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. *Med. Care.* 40:353-358.
- Stuifbergen AK, Harrison TC (2003). Complementary and alternative therapy use in persons with multiple sclerosis. *Rehabil. Nurs.* 28:141-147
- Tafreshi AP, Ahmadi A, Ghaffarpur M, Mostafavi H, Rezaeizadeh H, Minaie B, Faghihzadeh S, Naseri M (2008). An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. *Phytother. Res.* 22:1083-1086.
- Vaney C, Heinzl-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M (2004). Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Mult. Scler.* 10:339-340.
- Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis: multicentre randomized placebo-controlled trial, the lancet. *Lancet.* 362:1517-1526.